Asad Durrani is an Ophthalmology physician affiliated with Thomas Jefferson University. OpenAlex indexes 52 publications with 662 citations (h-index 14).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
840 Walnut St Ste 1020
Philadelphia, PA 191075109
Telephone
800-331-6634Provider last certified this registry record 5 Jul 2022.
Industry payments
8 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Sight Sciences, Inc.Program year20251 payment
- Bausch & Lomb Americas Inc.Program year20241 payment
- Genentech USA, Inc.Program year20241 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Sensory organs
100%Corticosteroid53.7%Prednisolone Acetate100%Part D≥122 patientsPolymyxin-class Antibacterial41.3%Polymyxin B Sul-Trimethoprim100%Part D≥125 patients+ 1 more class in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Reducing rates of endophthalmitis from intravitreal injections – strategies and areas of controversy
Current Opinion in Ophthalmology
2025 - Conversion to faricimab after prior anti-vascular endothelial growth factor therapy for persistent diabetic macular oedema
British Journal of Ophthalmology
2024 - Assessing ChatGPT-3.5 Versus ChatGPT-4 Performance in Surgical Treatment of Retinal Diseases: A Comparative Study
Ophthalmic surgery, lasers & imaging retina
2024 - Long-Term Stability, Sterility, And Cost-Effectiveness of 0.05% Chlorhexidine Gluconate as Antisepsis for Intravitreal Injection
Journal of Ocular Pharmacology and Therapeutics
2024
Similar KOLs
Other experts from the same institution or the same specialty.
Carol Shields, MD
Thomas Jefferson University
Joseph Bavaria, MD
Thomas Jefferson University
Michele Meltzer, MD
Thomas Jefferson University
Marinos Dalakas, MD
Thomas Jefferson University
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”